Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Stock Information for Vor Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vor Biopharma Inc.

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.